[Haptoglobin polymorphism in patients with inflammatory bowel diseases]
Mária Papp1, Péter László Lakatos,
1Debreceni Egyetem, Orvos- es Egészségtudományi Centrum, Belgyógyászati Intézet, Gasztroenterológiai Tanszék, Debrecen. drpappm@yahoo.com
Orvosi Hetilap
|November 8, 2006
Summary
The haptoglobin-1 allele is linked to a higher risk of Crohn's disease. Haptoglobin phenotypes influence Crohn's disease behavior and the occurrence of primary sclerosing cholangitis.
Area of Science:
- Genetics
- Immunology
- Gastroenterology
Context:
- Haptoglobin (Hp) phenotypes are known to influence inflammatory diseases.
- Understanding Hp polymorphism is crucial for inflammatory bowel disease (IBD) research.
Purpose:
- To investigate the distribution of haptoglobin (Hp) polymorphism in Hungarian Crohn's disease (CD) patients.
- To explore the association between Hp phenotypes and disease characteristics in CD.
Summary:
- The haptoglobin-1 allele frequency was significantly higher in Hungarian Crohn's disease patients (0.395) compared to controls (0.345).
- Hp phenotype was associated with disease behavior (B1 and B2) in CD patients.
- An increased frequency of primary sclerosing cholangitis was observed in individuals with haptoglobin 2-2 phenotype.
Impact:
- Haptoglobin-1 allele is associated with Crohn's disease.
- Haptoglobin phenotypes demonstrate a disease-modifying effect on Crohn's disease behavior and primary sclerosing cholangitis risk.
More Related Videos
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:49Multiple Allele Traits
The Concept of Multiple Allelism
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...